Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on August 15, 2026 to 13 new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4). The awards total 4,676 time-based restricted stock units, vesting in four equal annual installments over four years, contingent on continued employment.

Market Context

A prior inducement-award release was followed by a -0.06% 24-hour price reaction. This announcement ...

Analysis

A prior inducement-award release was followed by a -0.06% 24-hour price reaction. This announcement likewise concerned employee RSUs, while the platform records low short positioning; subsequent award and insider filings remain the watchpoint.

Key Figures

Grant date: August 15, 2026 Recipients: 13 new non-executive employees Restricted stock units: 4,676 time-based RSUs +2 more

5 metrics

Grant date August 15, 2026 Equity inducement awards

Recipients 13 new non-executive employees Equity inducement awards

Restricted stock units 4,676 time-based RSUs Aggregate employee awards

Vesting schedule 4 equal installments First through fourth anniversaries of grant date

Nasdaq listing rule 5635(c)(4) Compensation Committee approval

Historical Context

5 past events · Latest: Aug 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 12	Board appointment	Positive	+0.2%	Added John C. Reed, M.D., Ph.D. to the board and Science and Technology Committee
Aug 06	Inducement awards	Neutral	-0.1%	Granted 4,263 restricted stock units to ten new non-executive employees
Aug 06	Conference participation	Neutral	-0.7%	Announced participation in Canaccord Genuity's annual growth conference
Jul 30	Q2 earnings	Negative	-9.8%	Reported a $57.9 million net loss despite $364.3 million in quarterly revenue
Jul 21	Inducement awards	Neutral	-1.7%	Granted options and restricted stock units to ten new non-executive employees

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history showed negative 24-hour reactions to both prior inducement-award releases (-0.06% and -1.67%) and to the conference notice (-0.73%), while the board appointment was followed by +0.17%.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"The new employees received, in the aggregate, 4,676 time-based restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,676 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

What equity inducement awards did Madrigal Pharmaceuticals (MDGL) grant in August 2026?

Madrigal Pharmaceuticals granted a total of 4,676 time-based restricted stock units on August 15, 2026. According to the company, these equity awards were issued as inducement grants to 13 new non-executive employees under its 2025 Inducement Plan.

Who received the August 15, 2026 inducement equity awards from Madrigal Pharmaceuticals (NASDAQ:MDGL)?

The awards were granted to 13 new non-executive employees of Madrigal Pharmaceuticals. According to the company, these equity inducement grants were considered material to the employees’ acceptance of employment with Madrigal under its 2025 Inducement Plan.

How do the Madrigal Pharmaceuticals (MDGL) restricted stock units granted on August 15, 2026 vest?

All 4,676 restricted stock units vest in four equal annual installments on each of the first through fourth anniversaries of the grant date. According to Madrigal, vesting is subject to each employee’s continued employment on the applicable vesting date.

Under which plan were the 2026 inducement awards for Madrigal Pharmaceuticals (MDGL) employees granted?

The inducement awards were granted under Madrigal’s 2025 Inducement Plan. According to the company, these equity awards were approved by its independent Compensation Committee and structured as material inducements for the 13 new non-executive employees to join Madrigal.

How does Nasdaq Listing Rule 5635(c)(4) relate to Madrigal Pharmaceuticals’ August 2026 inducement grants (MDGL)?

The grants were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which addresses equity awards as employment inducements. According to Madrigal, the independent Compensation Committee approved these restricted stock units as inducement awards for new non-executive employees.